fdalawblog.net

Evaluation du site fdalawblog.net

FDA Law Blog

 Généré le 30 Mars 2026 11:08

Vieilles statistiques? UPDATE !

Le score est de 54/100

Optimisation du contenu

Titre

FDA Law Blog

Longueur : 12

Parfait, votre titre contient entre 10 et 70 caractères.

Description

where experts go to learn about the FDA

Longueur : 39

Idéalement, votre balise META description devrait contenir entre 70 et 160 caractères (espaces compris). Utilisez cet outil gratuit pour calculer la longueur du texte.

Mots-clefs

Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.

Propriétés Open Graph

Bien, cette page profite des balises META Open Graph.

Propriété Contenu
type website
title FDA Law Blog
description where experts go to learn about the FDA
url https://www.thefdalawblog.com/
site_name FDA Law Blog
image https://s0.wp.com/i/blank.jpg
locale en_US

Niveaux de titre

H1 H2 H3 H4 H5 H6
15 0 4 0 0 0
  • [H1] Hospital Employee Controlled Substance Diversion Is a Topic at Upcoming IAHSS Conference
  • [H1] Job Opportunity: HPM Seeks Associate Drug Development Attorney
  • [H1] DEA Fine Tunes Power of Attorney and DEA-222 Requirements
  • [H1] No, GRAS Isn’t Just About Vinegar
  • [H1] WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – April 14th, 10:00 to 11:00 ET
  • [H1] Job Opportunity: HPM Seeks Junior to Mid-Level Attorney with Healthcare Law Experience
  • [H1] PK Studies in the Crosshairs: FDA Revises Biosimilar Development Guidance
  • [H1] Don’t Just Say “We’ll Fix It”: FDA Wants Real Investigations in Your 483 Response
  • [H1] FDA Signals Potential Updates to SUPAC Guidances—Comments Due June 1, 2026
  • [H1] 6-4-2 Blastoff! FDA’s New NDC Format Coming … in 2033
  • [H1] WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – March 17th, 10:00 to 11:00 ET
  • [H1] The Dark Side of PREA . . . . But is There a Way to Churn the Cream Into Butter and Crawl Out? Catch Me If You Can!
  • [H1] HPM to Host Complimentary Webinar on US Regulatory Strategy for MedTech Startups
  • [H1] FDA Guidance Sheds (Some) New Light on 3-Year New Clinical Investigation Exclusivity
  • [H1] Federal Court Preliminarily Enjoins Texas Labeling Law
  • [H3] Search FDA Law Blog
  • [H3] Subscribe
  • [H3] Latest Tweets
  • [H3] Awards & Honors

Images

Nous avons trouvé 2 image(s) sur cette page Web.

Bien, la plupart ou la totalité de vos images possèdent un attribut alt

Ratio texte/HTML

Ratio : 15%

Bien, le ratio de cette page texte/HTML est supérieur à 15, mais inférieur à 25 pour cent.

Flash

Parfait, aucun contenu FLASH n'a été détecté sur cette page.

Iframe

Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.

Réécriture d'URLs

Bien. Vos liens sont optimisés!

Tiret bas dans les URLs

Nous avons détectés des soulignements dans vos URLs. Vous devriez plutôt utiliser des tirets pour optimiser votre référencement.

Liens dans la page

Nous avons trouvé un total de 162 lien(s) dont 16 lien(s) vers des fichiers

Texte d'ancre Type Juice
- Interne Passing Juice
Practices Externe Passing Juice
Industries Externe Passing Juice
FDA Regulatory Categories Externe Passing Juice
Professionals Externe Passing Juice
About Us Externe Passing Juice
Contact Externe Passing Juice
News &amp Events Externe Passing Juice
Hospital Employee Controlled Substance Diversion Is a Topic at Upcoming IAHSS Conference Externe Passing Juice
Job Opportunity: HPM Seeks Associate Drug Development Attorney Externe Passing Juice
DEA Fine Tunes Power of Attorney and DEA-222 Requirements Externe Passing Juice
No, GRAS Isn’t Just About Vinegar Externe Passing Juice
WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – April 14th, 10:00 to 11:00 ET Externe Passing Juice
180-Day Exclusivity Tracker Interne Passing Juice
FDA Citizen Petition Tracker Interne Passing Juice
REMS Tracker (Historical – Not Recently Updated) Interne Passing Juice
FDA Legislation Tracker Interne Passing Juice
Orange Book Archives Interne Passing Juice
ANDA Paragraph IV Patent Certifications List Archives Externe Passing Juice
Generic Drug Labeling Carve-Out Scorecard Interne Passing Juice
Biosimilars State Legislation Scorecard (Historical – Not Recently Updated)  Interne Passing Juice
Big Molecule Watch Blog Externe Passing Juice
Bloomberg BNA Health Care Blog Externe Passing Juice
Drug and Device Law Blog Externe Passing Juice
Eye on FDA Externe Passing Juice
FDA Matters Externe Passing Juice
Harvard Law Bill of Health Externe Passing Juice
IN VIVO Blog Externe Passing Juice
Internet Drug News.com Externe Passing Juice
Lachman Consultants Blog Externe Passing Juice
Medical Devices Today Externe Passing Juice
Orange Book Blog Externe Passing Juice
Pharma IQ Externe Passing Juice
Pharmalot Externe Passing Juice
SCOTUS Blog Externe Passing Juice
The Volokh Conspiracy Externe Passing Juice
WLF Legal Pulse Externe Passing Juice
Centers for Medicare & Medicaid Services Externe Passing Juice
Drug Enforcement Administration Externe Passing Juice
Food and Drug Administration Externe Passing Juice
Advertising and Promotion (Federal Trade Commission) Externe Passing Juice
Advertising and Promotion (OPDP) Externe Passing Juice
Animal Drugs and Feeds Externe Passing Juice
Biosimilars Externe Passing Juice
Cannabis Externe Passing Juice
cGMP Compliance Externe Passing Juice
Consumer Product Safety Commission Externe Passing Juice
Controlled Substances Externe Passing Juice
Cosmetics Externe Passing Juice
COVID19 Externe Passing Juice
Current Affairs Externe Passing Juice
Dietary Supplements Externe Passing Juice
Drug Development Externe Passing Juice
Drug Enforcement Administration Externe Passing Juice
Enforcement Externe Passing Juice
FDA News Externe Passing Juice
Foods Externe Passing Juice
Foods and Dietary Supplements Externe Passing Juice
Fraud and Abuse Externe Passing Juice
Government Pricing Externe Passing Juice
Hatch-Waxman Externe Passing Juice
Health Care Externe Passing Juice
Health Privacy Externe Passing Juice
Import/Export Externe Passing Juice
In Vitro Diagnostic Devices Externe Passing Juice
Jobs Externe Passing Juice
Medical Devices Externe Passing Juice
Miscellaneous Externe Passing Juice
Orphan Drugs Externe Passing Juice
OTC Drugs and Cosmetics Externe Passing Juice
Prescription Drugs and Biologics Externe Passing Juice
Product Jurisdiction and Combination Products Externe Passing Juice
Reimbursement Externe Passing Juice
Tissue Products Externe Passing Juice
Tobacco Externe Passing Juice
Uncategorized Externe Passing Juice
Larry K. Houck Externe Passing Juice
announced Externe Passing Juice
Larry Houck Externe Passing Juice
here Externe Passing Juice
New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222) Externe Passing Juice
Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments Externe Passing Juice
Ricardo Carvajal Externe Passing Juice
proposed rule Externe Passing Juice
Food and Dietary Supplement Safety and Regulation Conference Externe Passing Juice
Catherine Drew Externe Passing Juice
Sara W. Koblitz Externe Passing Juice
2026-04-14 – Webinar – Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe | Hyman Phelps registration Externe Passing Juice
Job Opportunity: HPM Seeks Junior to Mid-Level Attorney with Healthcare Law Experience Externe Passing Juice
PK Studies in the Crosshairs: FDA Revises Biosimilar Development Guidance Externe Passing Juice
Fabiola C. Gomez, Ph.D., CMC Regulatory Expert Externe Passing Juice
announced Externe Passing Juice
final guidance Externe Passing Juice
requesting comment Externe Passing Juice
According to FDA Externe Passing Juice
Don’t Just Say “We’ll Fix It”: FDA Wants Real Investigations in Your 483 Response Externe Passing Juice
Kalie E. Richardson Externe Passing Juice
Charles D. Snow Externe Passing Juice
Anne K. Walsh Externe Passing Juice
calls Externe Passing Juice
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection Externe Passing Juice
21 CFR 211.192 Externe Passing Juice
Nonbinding Feedback After Certain FDA Inspections of Device Establishments Guidance (April 2020) Externe Passing Juice
previously Externe Passing Juice
ICH Q9 Quality Risk Management Externe Passing Juice
ICH Q10 Pharmaceutical Quality System Externe Passing Juice
Docket FDA-2025-D-1504 Externe Passing Juice
Post-Warning Letter Meetings Under GDUFA Guidance for Industry Externe Passing Juice
device Externe Passing Juice
FDA Signals Potential Updates to SUPAC Guidances—Comments Due June 1, 2026 Externe Passing Juice
notice Externe Passing Juice
6-4-2 Blastoff! FDA’s New NDC Format Coming … in 2033 Externe Passing Juice
Karla L. Palmer Externe Passing Juice
Dara Katcher Levy Externe Passing Juice
Final Rule Revising the National Drug Code Format and Drug Label Barcode Requirements Externe Passing Juice
900-year supply Externe Passing Juice
Proposed Rule Externe Passing Juice
current version Externe Passing Juice
Frequently Asked Questions (FAQs) by the Pharmaceutical Industry in Preparing for the U.S. DSCSA Externe Passing Juice
acknowledges Externe Passing Juice
Bernstein Rx Solutions, LLC Externe Passing Juice
WEBINAR: Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe – March 17th, 10:00 to 11:00 ET Externe Passing Juice
2026-03-17 – Webinar – Navigating Orphan Medicines Regulation: Strategic Insights from the US and Europe | Hyman Phelps registration Externe Passing Juice
The Dark Side of PREA . . . . But is There a Way to Churn the Cream Into Butter and Crawl Out? Catch Me If You Can! Externe Passing Juice
Kurt R. Karst Externe Passing Juice
Two Little Mice Externe Passing Juice
Pediatric Rule Externe Passing Juice
Pediatric Research Equity Act Externe Passing Juice
Ass’n of Am. Physicians & Surgeons, Inc. v. United States FDA, 226 F. Supp. 2d 204 (D.D.C. 2002) Externe Passing Juice
Pediatric Testing of Prescription Drugs: The Food and Drug Administration’s Carrot and Stick for the Pharmaceutical Industry, 49 Am. U.L. Rev. 739 (2000) Externe Passing Juice
guidance Externe Passing Juice
according to FDA Externe Passing Juice
public list Externe Passing Juice
Public Law No. 119-75 Externe Passing Juice
2012 Food and Drug Administration Safety and Innovation Act Externe Passing Juice
BPCA/PREA Report to Congress Externe Passing Juice
FDA’s Anti-Franchising Policy: What Is It and Where Did It Come From? (Mar 4, 2015) Interne Passing Juice
2012 Letter Decision Externe Passing Juice
HPM to Host Complimentary Webinar on US Regulatory Strategy for MedTech Startups Externe Passing Juice
Jennifer Newberger Externe Passing Juice
Lisa Baumhardt Externe Passing Juice
here Externe Passing Juice
FDA Guidance Sheds (Some) New Light on 3-Year New Clinical Investigation Exclusivity Externe Passing Juice
Sara W. Koblitz Externe Passing Juice
Sarah Wicks Externe Passing Juice
New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers Externe Passing Juice
here Externe Passing Juice
here Externe Passing Juice
Federal Court Preliminarily Enjoins Texas Labeling Law Externe Passing Juice
Riëtte van Laack Externe Passing Juice
previously reported Externe Passing Juice
filed a complaint Externe Passing Juice
filed a motion for preliminary injunction Externe Passing Juice
a preliminary injunction Externe Passing Juice
2 Externe Passing Juice
3 Externe Passing Juice
10 Externe Passing Juice
20 Externe Passing Juice
Last » Externe Passing Juice
Tweets by @fdalawblog Externe Passing Juice
Disclaimer Externe Passing Juice
Careers Externe Passing Juice

Mots-clefs

Nuage de mots-clefs

fda clinical product approval guidance new exclusivity ndc response drug

Cohérence des mots-clefs

Mot-clef Contenu Titre Mots-clefs Description Niveaux de titre
fda 169
drug 90
product 71
exclusivity 62
new 51

Ergonomie

Url

Domaine : fdalawblog.net

Longueur : 14

Favicon

Génial, votre site web dispose d'un favicon.

Imprimabilité

Génial. L'impression est optimisée grâce aux styles CSS.

Langue

Bien. Votre langue est : en.

Dublin Core

Cette page ne profite pas des métadonnées Dublin Core.

Document

Doctype

HTML 5

Encodage

Parfait. Votre charset est UTF-8.

Validité W3C

Erreurs : 0

Avertissements : 0

E-mail confidentialité

Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.

HTML obsolètes

Tags obsolètes Occurrences
<u> 1

Les balises HTML obsolètes sont des balises qui ne sont plus utilisés. Il est recommandé de supprimer ou de remplacer ces balises HTML, car elles sont désormais obsolètes.

Astuces vitesse

Excellent, votre site n'utilise pas de tableaux imbriqués.
Mauvais, votre site web utilise des styles css inline.
Mauvais, votre site web contient trop de fichiers CSS (plus de 4).
Mauvais, votre site web contient trop de fichiers javascript (plus de 6).
Parfait : votre site tire parti de gzip.

Mobile

Optimisation mobile

Icône Apple
Méta tags viewport
Contenu FLASH

Optimisation

Sitemap XML

Votre site web dispose d’une sitemap XML, ce qui est optimal.

https://www.thefdalawblog.com/wp-sitemap.xml

Robots.txt

https://fdalawblog.net/robots.txt

Votre site dispose d’un fichier robots.txt, ce qui est optimal.

Mesures d'audience

Votre site web dispose d’une outil d'analytics, ce qui est optimal.

   Google Analytics

PageSpeed Insights

Dispositif
Les catégories

Free SEO Testing Tool

Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web